Review
Accepted on 25 Apr 2024
The Intricate Interplay between Cancer Stem Cells and Cell-Of-Origin of Cancer: Implications for Therapeutic Strategies
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1404628
Type at least 3 characters
1,667 articles
Articles
Review
Accepted on 25 Apr 2024
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1402128
Review
Published on 25 Apr 2024
Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1375729
- 131 views
Mini Review
Accepted on 24 Apr 2024
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1394702
Review
Accepted on 24 Apr 2024
Current Status, Challenges and Prospects of Antifouling Materials for Oncology Applications
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1391293
Mini Review
Accepted on 22 Apr 2024
Advances in CAR-NK Cell Therapy for Lung Cancer: Is it a better choice in the future?
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1390006
Mini Review
Accepted on 19 Apr 2024
Nanoparticle Enhanced PD-1/PD-L1 Targeted Combination Therapy for Triple Negative Breast Cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1393492
Editorial
Published on 19 Apr 2024
Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1411836
- 191 views
Clinical Trial
Published on 19 Apr 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1386190
- 228 views
Review
Published on 18 Apr 2024
Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1389713
- 123 views
Brief Research Report
Published on 18 Apr 2024
Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1344852
- 431 views
Review
Accepted on 16 Apr 2024
The Use of Photodynamic Therapy in Medical Practice
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1373263
Perspective
Accepted on 15 Apr 2024
IMMUNOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY FOR OLDER PATIENTS WITH NON-METASTATIC RENAL CANCER UNFIT FOR SURGERY OR DECLINE NEPHRECTOMY: PRACTICAL PROPOSAL BY THE INTERNATIONAL GERIATRIC RADIOTHERAPY GROUP
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1391464
Original Research
Accepted on 15 Apr 2024
The HER2 Flip-HER2 amplification of tumor cells in the cerebrospinal fluid (CSF-TCs) of Breast Cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 Therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1402651
Review
Accepted on 11 Apr 2024
KRAS G12C inhibitor combination therapies: current evidence and challenge
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1380584
Correction
Accepted on 09 Apr 2024
Corrigendum: The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1414456